Robinson B S, Everson J S
Department of Microbiology, University of Southampton Medical School, U.K.
Arch Virol. 1992;125(1-4):273-86. doi: 10.1007/BF01309644.
Respiratory syncytial (RS) virus continues to cause serious human respiratory disease and no prophylactic vaccine is yet available. Serum antibodies to RS virus fusion protein (F) that have the appropriate specificities and activities could confer protection against severe RS virus infections. To explore human serum antibody responses to RS virus F we first characterised four epitopes on F and then measured the concentrations of human serum antibodies to these sites for 389 sera. Individuals varied in serum antibody concentration to the epitopes. The distribution patterns of the concentrations of antibodies reactive to each epitope were different. Antigenic variation of F at these epitopes in Southampton RS virus isolates was examined by immunofluorescence. The F proteins from different isolates varied within and between RS virus subtypes which co-circulated in the outbreak of winter 1985-1986. Variations in F detected by immunofluorescence were consistent with differences between the strains' susceptibilities to monoclonal antibody antiviral action.
呼吸道合胞（RS）病毒持续引发严重的人类呼吸道疾病，目前尚无预防性疫苗。具有适当特异性和活性的针对RS病毒融合蛋白（F）的血清抗体可提供针对严重RS病毒感染的保护。为了探究人类血清对RS病毒F的抗体反应，我们首先对F上的四个表位进行了表征，然后测量了389份血清中针对这些位点的人类血清抗体浓度。个体针对这些表位的血清抗体浓度各不相同。对每个表位有反应的抗体浓度的分布模式也不同。通过免疫荧光检查了南安普敦RS病毒分离株中这些表位处F的抗原变异。来自不同分离株的F蛋白在1985 - 1986年冬季疫情中共存的RS病毒亚型内和亚型之间存在差异。通过免疫荧光检测到的F的变异与各毒株对单克隆抗体抗病毒作用的敏感性差异一致。
